Two issues in the news this week caught my attention, both related to treatments hoped to ease the effects of Alzheimer’s disease. These stories shine a light on the delicate balance of those willing to try anything – and those, such as the FDA, who must weigh safety and professional standards.
This week we received another disappointing announcement from Baxter that Gammagard, an immune globulin, did not prove to improve or maintain functioning in the study sample. And, Alan Zarembo of the Los Angeles Times, writes a hauntingly honest piece on a husband willing to try an unproven medication for his wife.
Alzheimer’s disease is in the news almost daily. While often the stories are emotional and not always encouraging, we must never lose hope.